Sustained Remission in Patients with Primary Immune Thrombocytopenia after Romiplostim Tapering and Discontinuation: A Case Series in Real Life Management in Spain
Joint Authors
Mingot-Castellano, María Eva
Grande-García, Carlos
Valcárcel-Ferreiras, David
Conill-Cortés, Clara
de Olivar-Oliver, Loreto
Source
Issue
Vol. 2017, Issue 2017 (31 Dec. 2017), pp.1-8, 8 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2017-06-11
Country of Publication
Egypt
No. of Pages
8
Main Subjects
Abstract EN
Romiplostim, a thrombopoietin-receptor agonist (TPO-ra), is a highly effective option in primary immune thrombocytopenia (ITP), with 80–90% of patients achieving platelet responses after few weeks of treatment.
The evidence showing remissions, that is, sustained platelet counts after romiplostim discontinuation, in patients with ITP refractory to immunosuppressive therapy is steadily increasing.
However, there is a lack of guidelines or recommendations addressing how and when to taper romiplostim in clinical practice in patients maintaining elevated and stable platelet counts.
Furthermore, given the high heterogeneity of ITP patients, no associated predictive factors have been currently identified.
Here, we present 4 representative clinical cases of the daily clinical practice in Spain comprising newly diagnosed, persistent, and both splenectomized and nonsplenectomized chronic ITP patients treated with romiplostim, achieving and maintaining clinical remission (platelet count ≥ 50 × 109/L for 24 consecutive weeks in the absence of any treatment for ITP) after treatment tapering and discontinuation, without observed safety concerns.
Prospective studies identifying clinical and biological predictive factors of sustained response are warranted.
American Psychological Association (APA)
Mingot-Castellano, María Eva& Grande-García, Carlos& Valcárcel-Ferreiras, David& Conill-Cortés, Clara& de Olivar-Oliver, Loreto. 2017. Sustained Remission in Patients with Primary Immune Thrombocytopenia after Romiplostim Tapering and Discontinuation: A Case Series in Real Life Management in Spain. Case Reports in Hematology،Vol. 2017, no. 2017, pp.1-8.
https://search.emarefa.net/detail/BIM-1145856
Modern Language Association (MLA)
Mingot-Castellano, María Eva…[et al.]. Sustained Remission in Patients with Primary Immune Thrombocytopenia after Romiplostim Tapering and Discontinuation: A Case Series in Real Life Management in Spain. Case Reports in Hematology No. 2017 (2017), pp.1-8.
https://search.emarefa.net/detail/BIM-1145856
American Medical Association (AMA)
Mingot-Castellano, María Eva& Grande-García, Carlos& Valcárcel-Ferreiras, David& Conill-Cortés, Clara& de Olivar-Oliver, Loreto. Sustained Remission in Patients with Primary Immune Thrombocytopenia after Romiplostim Tapering and Discontinuation: A Case Series in Real Life Management in Spain. Case Reports in Hematology. 2017. Vol. 2017, no. 2017, pp.1-8.
https://search.emarefa.net/detail/BIM-1145856
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1145856